Page 484 - Read Online

Agdamag et al. Vessel Plus 2020;4:42 I http://dx.doi.org/10.20517/2574-1209.2020.60 Page 9 of 9

Transplantation 2020;104:e38-9.
53. Walley KR, Thain KR, Russell JA, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci
Transl Med 2014;6:258ra143.
54. Bjerre KP, Clemmensen TS, Poulsen SH, et al. Micro- and macrovascular cardiac allograft vasculopathy in relation to 91 cardiovascular
biomarkers in heart transplant recipients-An exploratory study. Clin Transplant 2020;e14133.
55. Broch K, Gude E, Karason K, et al. Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De-novo heart
transplant recipients: design of the randomized controlled EVOLVD trial. Clin Transplant 2020;34:e13984.
56. Fearon W. National Institute of Health, US National Library of Medicine, clinicaltrials.gov. PCSK9 Inhibition After Heart Transplantation.
Available from: https://clinicaltrials.gov/ct2/show/NCT03537742. [Last accessed on 9 Dec 2020]
57. Di Nora C, Sponga S, Livi U. Safety and efficacy of PCSK9 inhibitor treatment in heart transplant patients. Transplantation
2019;103:e58.